CDK8-IN-6

• UNSPSC Description:

  CDK8-IN-6 (compound 9) is a potent cyclin-dependent kinase 8 (CDK8) inhibitor with an Kd of 13 nM. CDK8-IN-6 shows cytotoxicity for MOLM-13, OCI-AML3, MV4-11, NRK and H9c2 cells with IC50s of 11.2, 7.5, 8.6, 20.5, 12.5-25 µM, respectively. CDK8-IN-6 has the potential for the research of AML-cancer[1].

• Target Antigen:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk8-in-6.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C[C@@]12C(C3=CC(Cl)=CN=C3)=CC[C@@]1([H])[C@]4([H])CC[C@@]5([H])C[C@H](N(C)C)CC[C@]5(C)[C@@]4([H])CC2

• Molecular Weight:

  413.04

• References & Citations:

  [1]Solum E, et al. New CDK8 inhibitors as potential anti-leukemic agents - Design, synthesis and biological evaluation. Bioorg Med Chem. 2020 May 15;28(10):115461.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2415156-27-1